DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Hunter SF, Arnold DL, Coles AJ , et al.
The efficacy of alemtuzumab is maintained in patients who develop thyroid adverse events.
Poster presented at: 67th American Academy of Neurology Annual Meeting; April 18–25, 2015; Washington, DC
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.